BCHM.Y Stock Overview

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details

BCHM.Y fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	5/6
Financial Health	6/6
Dividends	3/6

Rewards

Price-To-Earnings ratio (37x) is below the Life Sciences industry average (43.8x)

Earnings are forecast to grow 17.76% per year

Earnings grew by 15.3% over the past year

Risk Analysis

No risks detected for BCHM.Y from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Bachem Holding AG Competitors

Sotera Health

NasdaqGS:SHC

US$3.7b

Stevanato Group

NYSE:STVN

US$6.2b

Charles River Laboratories International

NYSE:CRL

US$8.4b

Bruker

NasdaqGS:BRKR

US$8.6b

Price History & Performance

Summary of share price highs, lows and changes for Bachem Holding
Historical stock prices
Current Share Price	CHF 6.25
52 Week High	CHF 10.18
52 Week Low	CHF 6.17
Beta	0.75
1 Month Change	-3.40%
3 Month Change	-22.65%
1 Year Change	5.22%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-33.86%

Recent updates

Shareholder Returns

	BCHM.Y	US Life Sciences	US Market
7D	1.3%	1.5%	3.2%
1Y	5.2%	-0.1%	24.2%

Return vs Industry: BCHM.Y exceeded the US Life Sciences industry which returned -0.1% over the past year.

Return vs Market: BCHM.Y underperformed the US Market which returned 24.2% over the past year.

Price Volatility

Is BCHM.Y's price volatile compared to industry and market?
BCHM.Y volatility
BCHM.Y Average Weekly Movement	8.4%
Life Sciences Industry Average Movement	9.5%
Market Average Movement	6.5%
10% most volatile stocks in US Market	18.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: BCHM.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BCHM.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1971	2,009	Thomas Meier	www.bachem.com

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.

Bachem Holding AG Fundamentals Summary

How do Bachem Holding's earnings and revenue compare to its market cap?
BCHM.Y fundamental statistics
Market cap	US$4.61b
Earnings (TTM)	US$124.39m
Revenue (TTM)	US$632.83m

37.0x

P/E Ratio

7.3x

P/S Ratio

Is BCHM.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BCHM.Y income statement (TTM)
Revenue	CHF 577.77m
Cost of Revenue	CHF 398.41m
Gross Profit	CHF 179.36m
Other Expenses	CHF 65.79m
Earnings	CHF 113.57m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)	1.51
Gross Margin	31.04%
Net Profit Margin	19.66%
Debt/Equity Ratio	0%

How did BCHM.Y perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

53%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/20 13:12
End of Day Share Price	2025/01/16 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bachem Holding AG is covered by 23 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Volker Bosse	Baader Helvea Equity Research
Thomas Meyer	Baader Helvea Equity Research
Konstantin Wiechert	Baader Helvea Equity Research

Bachem Holding OTCPK:BCHM.Y Stock Report